1556 related articles for article (PubMed ID: 26711051)
1. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors.
Zhu Y; Tchkonia T; Fuhrmann-Stroissnigg H; Dai HM; Ling YY; Stout MB; Pirtskhalava T; Giorgadze N; Johnson KO; Giles CB; Wren JD; Niedernhofer LJ; Robbins PD; Kirkland JL
Aging Cell; 2016 Jun; 15(3):428-35. PubMed ID: 26711051
[TBL] [Abstract][Full Text] [Related]
2. New agents that target senescent cells: the flavone, fisetin, and the BCL-X
Zhu Y; Doornebal EJ; Pirtskhalava T; Giorgadze N; Wentworth M; Fuhrmann-Stroissnigg H; Niedernhofer LJ; Robbins PD; Tchkonia T; Kirkland JL
Aging (Albany NY); 2017 Mar; 9(3):955-963. PubMed ID: 28273655
[TBL] [Abstract][Full Text] [Related]
3. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs.
Zhu Y; Tchkonia T; Pirtskhalava T; Gower AC; Ding H; Giorgadze N; Palmer AK; Ikeno Y; Hubbard GB; Lenburg M; O'Hara SP; LaRusso NF; Miller JD; Roos CM; Verzosa GC; LeBrasseur NK; Wren JD; Farr JN; Khosla S; Stout MB; McGowan SJ; Fuhrmann-Stroissnigg H; Gurkar AU; Zhao J; Colangelo D; Dorronsoro A; Ling YY; Barghouthy AS; Navarro DC; Sano T; Robbins PD; Niedernhofer LJ; Kirkland JL
Aging Cell; 2015 Aug; 14(4):644-58. PubMed ID: 25754370
[TBL] [Abstract][Full Text] [Related]
4. BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer.
Shahbandi A; Rao SG; Anderson AY; Frey WD; Olayiwola JO; Ungerleider NA; Jackson JG
Cell Death Differ; 2020 Nov; 27(11):3097-3116. PubMed ID: 32457483
[TBL] [Abstract][Full Text] [Related]
5. EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263.
Abdelgawad IY; Agostinucci K; Ismail SG; Grant MKO; Zordoky BN
Cells; 2022 Jun; 11(13):. PubMed ID: 35805077
[TBL] [Abstract][Full Text] [Related]
6. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.
Hickson LJ; Langhi Prata LGP; Bobart SA; Evans TK; Giorgadze N; Hashmi SK; Herrmann SM; Jensen MD; Jia Q; Jordan KL; Kellogg TA; Khosla S; Koerber DM; Lagnado AB; Lawson DK; LeBrasseur NK; Lerman LO; McDonald KM; McKenzie TJ; Passos JF; Pignolo RJ; Pirtskhalava T; Saadiq IM; Schaefer KK; Textor SC; Victorelli SG; Volkman TL; Xue A; Wentworth MA; Wissler Gerdes EO; Zhu Y; Tchkonia T; Kirkland JL
EBioMedicine; 2019 Sep; 47():446-456. PubMed ID: 31542391
[TBL] [Abstract][Full Text] [Related]
7. Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity.
González-Gualda E; Pàez-Ribes M; Lozano-Torres B; Macias D; Wilson JR; González-López C; Ou HL; Mirón-Barroso S; Zhang Z; Lérida-Viso A; Blandez JF; Bernardos A; Sancenón F; Rovira M; Fruk L; Martins CP; Serrano M; Doherty GJ; Martínez-Máñez R; Muñoz-Espín D
Aging Cell; 2020 Apr; 19(4):e13142. PubMed ID: 32233024
[TBL] [Abstract][Full Text] [Related]
8. Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-X
Saleh T; Carpenter VJ; Tyutyunyk-Massey L; Murray G; Leverson JD; Souers AJ; Alotaibi MR; Faber AC; Reed J; Harada H; Gewirtz DA
Mol Oncol; 2020 Oct; 14(10):2504-2519. PubMed ID: 32652830
[TBL] [Abstract][Full Text] [Related]
9. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
He Y; Zhang X; Chang J; Kim HN; Zhang P; Wang Y; Khan S; Liu X; Zhang X; Lv D; Song L; Li W; Thummuri D; Yuan Y; Wiegand JS; Ortiz YT; Budamagunta V; Elisseeff JH; Campisi J; Almeida M; Zheng G; Zhou D
Nat Commun; 2020 Apr; 11(1):1996. PubMed ID: 32332723
[TBL] [Abstract][Full Text] [Related]
10. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
11. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice.
Roos CM; Zhang B; Palmer AK; Ogrodnik MB; Pirtskhalava T; Thalji NM; Hagler M; Jurk D; Smith LA; Casaclang-Verzosa G; Zhu Y; Schafer MJ; Tchkonia T; Kirkland JL; Miller JD
Aging Cell; 2016 Oct; 15(5):973-7. PubMed ID: 26864908
[TBL] [Abstract][Full Text] [Related]
12. Discovery of piperlongumine as a potential novel lead for the development of senolytic agents.
Wang Y; Chang J; Liu X; Zhang X; Zhang S; Zhang X; Zhou D; Zheng G
Aging (Albany NY); 2016 Nov; 8(11):2915-2926. PubMed ID: 27913811
[TBL] [Abstract][Full Text] [Related]
13. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL.
Yosef R; Pilpel N; Tokarsky-Amiel R; Biran A; Ovadya Y; Cohen S; Vadai E; Dassa L; Shahar E; Condiotti R; Ben-Porath I; Krizhanovsky V
Nat Commun; 2016 Apr; 7():11190. PubMed ID: 27048913
[TBL] [Abstract][Full Text] [Related]
14. Identification of SYK inhibitor, R406 as a novel senolytic agent.
Cho HJ; Yang EJ; Park JT; Kim JR; Kim EC; Jung KJ; Park SC; Lee YS
Aging (Albany NY); 2020 May; 12(9):8221-8240. PubMed ID: 32379705
[TBL] [Abstract][Full Text] [Related]
15. Transient metabolic improvement in obese mice treated with navitoclax or dasatinib/quercetin.
Sierra-Ramirez A; López-Aceituno JL; Costa-Machado LF; Plaza A; Barradas M; Fernandez-Marcos PJ
Aging (Albany NY); 2020 Jun; 12(12):11337-11348. PubMed ID: 32584785
[TBL] [Abstract][Full Text] [Related]
16. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
Shi J; Zhou Y; Huang HC; Mitchison TJ
Cancer Res; 2011 Jul; 71(13):4518-26. PubMed ID: 21546570
[TBL] [Abstract][Full Text] [Related]
17. Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin.
Ahmadinejad F; Bos T; Hu B; Britt E; Koblinski J; Souers AJ; Leverson JD; Faber AC; Gewirtz DA; Harada H
Mol Pharmacol; 2022 Mar; 101(3):168-180. PubMed ID: 34907000
[TBL] [Abstract][Full Text] [Related]
18. Identification of HSP90 inhibitors as a novel class of senolytics.
Fuhrmann-Stroissnigg H; Ling YY; Zhao J; McGowan SJ; Zhu Y; Brooks RW; Grassi D; Gregg SQ; Stripay JL; Dorronsoro A; Corbo L; Tang P; Bukata C; Ring N; Giacca M; Li X; Tchkonia T; Kirkland JL; Niedernhofer LJ; Robbins PD
Nat Commun; 2017 Sep; 8(1):422. PubMed ID: 28871086
[TBL] [Abstract][Full Text] [Related]
19. Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells.
Li X; Li B; Ni Z; Zhou P; Wang B; He J; Xiong H; Yang F; Wu Y; Lyu X; Zhang Y; Zeng Y; Lian J; He F
Mol Cancer Ther; 2017 Sep; 16(9):1806-1818. PubMed ID: 28533436
[TBL] [Abstract][Full Text] [Related]
20. The Differential Effect of Senolytics on SASP Cytokine Secretion and Regulation of EMT by CAFs.
Bogdanova DA; Kolosova ED; Pukhalskaia TV; Levchuk KA; Demidov ON; Belotserkovskaya EV
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
